Mitoxantrone as a contributing factor in medication-related osteonecrosis of the jaws
Autor: | J.V. Bagan, Crispian Scully, Rafael Poveda, L. Bagan |
---|---|
Rok vydání: | 2016 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Odontología Antineoplastic Agents Breast Neoplasms 03 medical and health sciences Fatal Outcome 0302 clinical medicine Breast cancer stomatognathic system medicine Humans Adverse effect Mitoxantrone business.industry Osteonecrosis 030206 dentistry Middle Aged Bisphosphonate medicine.disease Metastatic breast cancer Surgery stomatognathic diseases Denosumab Otorhinolaryngology 030220 oncology & carcinogenesis Vomiting Female Oral Surgery medicine.symptom business Osteonecrosis of the jaw Jaw Diseases medicine.drug |
Zdroj: | INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname |
ISSN: | 0901-5027 |
DOI: | 10.1016/j.ijom.2015.09.025 |
Popis: | Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is usually initiated by dental surgery, but is occasionally exacerbated by other antiresorptive (denosumab) and anti-angiogenic therapies, and in such cases is currently termed medication-related osteonecrosis of the jaws (MRONJ). The case of a 58-year-old female with breast cancer who developed multiple and ultimately fatal metastases despite 3 years of treatment with chemotherapeutic drugs and intravenous bisphosphonates, is presented herein. Her malignant disease worsened and she was started on mitoxantrone. She developed a severe adverse reaction to this drug soon after starting treatment. As well as diarrhoea and vomiting, she had a very aggressive gingival inflammation with multiple ulcerations in both jaws and wide areas of necrotic bone, affecting the attached gingiva, and seemingly unrelated to dental plaque. These ulcerations and the exposed necrotic bone persisted for more that 6 months, until her death. This report describes a case in which severe gingival ulcerations that occurred after mitoxantrone treatment for metastatic breast cancer were a local factor that initiated MRONJ. Sin financiación 1.918 JCR (2016) Q2, 30/90 Dentistry, Oral Surgery & Medicine, 91/197 Surgery UEV |
Databáze: | OpenAIRE |
Externí odkaz: |